MX361765B - Formulacion homogenea que comprende acido graso poliinsaturado omega-3 y resveratrol para administracion oral. - Google Patents

Formulacion homogenea que comprende acido graso poliinsaturado omega-3 y resveratrol para administracion oral.

Info

Publication number
MX361765B
MX361765B MX2016013190A MX2016013190A MX361765B MX 361765 B MX361765 B MX 361765B MX 2016013190 A MX2016013190 A MX 2016013190A MX 2016013190 A MX2016013190 A MX 2016013190A MX 361765 B MX361765 B MX 361765B
Authority
MX
Mexico
Prior art keywords
resveratrol
oral administration
omega
homogenea
polyinsaturated
Prior art date
Application number
MX2016013190A
Other languages
English (en)
Spanish (es)
Other versions
MX2016013190A (es
Inventor
Giannini Giuseppe
SANTANIELLO Mosé
Original Assignee
Alfasigma Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alfasigma Spa filed Critical Alfasigma Spa
Publication of MX2016013190A publication Critical patent/MX2016013190A/es
Publication of MX361765B publication Critical patent/MX361765B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
MX2016013190A 2014-06-04 2015-03-26 Formulacion homogenea que comprende acido graso poliinsaturado omega-3 y resveratrol para administracion oral. MX361765B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14001941.5A EP2952209B1 (en) 2014-06-04 2014-06-04 Homogeneous formulations comprising omega-3 polyunsaturated fatty acids (n-3 PUFA) and resveratrol for oral administration
PCT/EP2015/056524 WO2015185238A1 (en) 2014-06-04 2015-03-26 Homogeneous formulation comprising omega-3 polyunsatured fatty acid and resveratrol for oral administration

Publications (2)

Publication Number Publication Date
MX2016013190A MX2016013190A (es) 2017-01-09
MX361765B true MX361765B (es) 2018-12-17

Family

ID=50884651

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016013190A MX361765B (es) 2014-06-04 2015-03-26 Formulacion homogenea que comprende acido graso poliinsaturado omega-3 y resveratrol para administracion oral.

Country Status (13)

Country Link
US (1) US10300035B2 (enExample)
EP (1) EP2952209B1 (enExample)
JP (1) JP6552526B2 (enExample)
CN (1) CN106456783B (enExample)
AU (1) AU2015271277A1 (enExample)
CA (1) CA2943000A1 (enExample)
EA (1) EA032717B1 (enExample)
ES (1) ES2666836T3 (enExample)
MX (1) MX361765B (enExample)
PL (1) PL2952209T3 (enExample)
PT (1) PT2952209T (enExample)
UA (1) UA118289C2 (enExample)
WO (1) WO2015185238A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20250006294A (ko) * 2022-05-06 2025-01-10 선포레스트 (베이징) 바이오팜 엘티디 세포막 막횡단 수송과 유동성을 조절하는 탄소사슬 물질, 제조 및 응용
CN114569726B (zh) * 2022-05-06 2022-10-28 太阳雨林(北京)生物医药有限公司 预防、阻止或治疗微生物感染的复合物及制备方法和用途

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1306722B1 (it) * 1999-10-08 2001-10-02 Sigma Tau Healthscience Spa Composizione per la prevenzione e/o il trattamento di disfunzionicircolatorie, comprendente derivati della l-carnitina ed estratti di
ITRM20020562A1 (it) 2002-11-06 2004-05-07 Sigma Tau Ind Farmaceuti Uso del resveratrolo per la preparazione di un medicamento utile per il trattamento delle infezioni da virus dell'influenza.
DK1863570T3 (da) * 2005-03-11 2011-06-20 Recon Oil Ind Private Ltd Synergistisk varmestabilt oliemedium med eicosapentaensyre (EPA) og decosahexaensyre (DHA)
DE202008003509U1 (de) * 2008-03-12 2009-10-15 Langhoff, Gertrud Pharmazeutische Zusammensetzung zur Prophylaxe und Behandlung der Arteriosklerose, sowie zur Schmerzbekämpfung und zur Entzündungshemmung
KR101100078B1 (ko) * 2008-03-27 2011-12-29 홉킨스바이오연구센터(주) 관절염 치료를 위한 약제학적 조성물
CN102665698A (zh) 2009-12-23 2012-09-12 迪菲安特制药有限责任公司 可用于治疗心血管疾病的联合组合物
WO2011120530A1 (en) 2010-03-31 2011-10-06 Lifecycle Phama A/S Porous tablets as carriers for liquid formulations
WO2011162802A1 (en) * 2010-06-21 2011-12-29 Virun, Inc. Compositions containing non-polar compounds
IT1400695B1 (it) 2010-06-21 2013-06-28 Labomar S R L Composizioni farmaceutiche e/o nutraceutiche contenenti principi attivi insolubili in acqua e procedimento per ottenerle.
CN102228089B (zh) * 2011-06-22 2013-02-20 刘升胜 一种天然复合食用植物健脑营养饮料
KR101418980B1 (ko) * 2012-04-24 2014-07-11 (주)바이오제닉스 난용성 물질을 가용화 하는 다중 라멜라 액정의 제조방법
EP2664329A1 (de) * 2012-05-15 2013-11-20 F. Holzer GmbH Ophthalmologisches Vehikelsystem
WO2014095628A1 (en) * 2012-12-17 2014-06-26 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Oral formulation containing a statin in omega-3 polyunsaturated fatty acids (n-3 pufa)

Also Published As

Publication number Publication date
ES2666836T3 (es) 2018-05-08
EP2952209B1 (en) 2018-03-28
CA2943000A1 (en) 2015-12-10
US10300035B2 (en) 2019-05-28
CN106456783A (zh) 2017-02-22
PL2952209T3 (pl) 2018-07-31
CN106456783B (zh) 2020-06-12
JP2017516820A (ja) 2017-06-22
EA032717B1 (ru) 2019-07-31
JP6552526B2 (ja) 2019-07-31
PT2952209T (pt) 2018-05-09
WO2015185238A1 (en) 2015-12-10
EA201692398A1 (ru) 2017-04-28
US20170119720A1 (en) 2017-05-04
AU2015271277A1 (en) 2016-11-10
EP2952209A1 (en) 2015-12-09
UA118289C2 (uk) 2018-12-26
MX2016013190A (es) 2017-01-09

Similar Documents

Publication Publication Date Title
CL2019003105A1 (es) Lípidos extraídos de plantas que comprenden ácidos grasos poliinsaturados de cadena larga. (divisional solicitud 201601560)
MX372724B (es) Formulaciones de acido eicosapentaenoico (epa).
PE20151864A1 (es) Composiciones nutricionales que contienen una fraccion enriquecida de lipido y usos del mismo
HK1206248A1 (en) Compositions of statins and omega-3 fatty acids
TW201613488A (en) Nutritional compositions containing oil blends and uses thereof
PH12014500105A1 (en) Fatty acid compositions
AR105144A1 (es) Composiciones nutricionales y métodos para promover el desarrollo cognitivo
BR112015020671A2 (pt) método de aumentar a biodisponibilidade da dha e outros nutrientes solúveis em lipídeos
IL283357A (en) Semifluorinated alkane compositions comprising omega-3 fatty acid ethyl esters
WO2016040570A3 (en) Dietary emulsion formulations and methods for using the same
CY1123942T1 (el) Συνθεσεις ωμεγα-3 λιπαρων οξεων για τη θεραπεια ασθενειων που επιφερουν βλαβη στο νευρικο συστημα
MX386098B (es) Analogos metabolicamente robustos de cyp-eicosanoides para el tratamiento de enfermedades cardiacas.
AR076184A1 (es) Formulaciones farmaceuticas que comprenden 9-cis-retinil esteres en un vehiculo lipidico. metodo.
CO2017001088A2 (es) Mezcla de ácidos grasos y palmitoiletanolamida para su uso en el tratamiento de patologías inflamatorias y alérgicas
MX2015007082A (es) Métodos de administración de composiciones que comprenden ácido docosapentanoico.
PL3784044T3 (pl) Kompozycje wielonienasyconych kwasów tłuszczowych wzbogacone w dha
MX361765B (es) Formulacion homogenea que comprende acido graso poliinsaturado omega-3 y resveratrol para administracion oral.
IN2014DN05811A (enExample)
CO2017005911A2 (es) Método para incrementar niveles de ácidos grasos de omega-3 en productos de carne de res por medio de administración de una dieta de pasto y algas
AR096564A1 (es) Composiciones nutricionales para bebés prematuros
PH12017500738A1 (en) Feeding algae to cattle at low doses to produce high omega 3 levels in beef
PL3809858T3 (pl) Kompozycje wielonienasyconych kwasów tłuszczowych wzbogacone w dha
BR112018070194A2 (pt) composto e composição para uso
SG11201811427YA (en) Dielectric fluid comprising fatty acid esters
GB201209344D0 (en) Omega-6 enriched pufa phospholipids

Legal Events

Date Code Title Description
GB Transfer or rights

Owner name: ALFASIGMA S.P.A.

FG Grant or registration